Loading
The trial that made radioligand therapy a standard: a radioactive drug homing to the somatostatin receptor held midgut neuroendocrine tumours in check far longer than high-dose octreotide, and it underpins Lutathera's approvals.
NETTER-1, trial NCT01578239 sponsored by Advanced Accelerator Applications and published in the New England Journal of Medicine in 2017, randomised 231 patients with inoperable, progressive, somatostatin receptor-positive midgut neuroendocrine tumours to 177Lu-Dotatate (four cycles, with octreotide) or high-dose octreotide LAR. Progression-free survival at 20 months was 65.2% with 177Lu-Dotatate against 10.8% with octreotide, and the response rate was 18% against 3%. The result supported the 2018 US and EU approvals of Lutathera and made peptide receptor radionuclide therapy the reference treatment after somatostatin analogues.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
231 enrolled.
Shares Dosimetry-personalised PRRT instead of four fixed cycles, Lutetium-177 dotatate, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Somatostatin analogues (octreotide, lanreotide), Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Lutetium-177 dotatate.
Shares Dosimetry-personalised PRRT instead of four fixed cycles, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares Dosimetry-personalised PRRT instead of four fixed cycles, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares Somatostatin analogues (octreotide, lanreotide), Small intestinal neuroendocrine tumours, Novartis, Neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours.
Shares Lutetium-177 dotatate, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.